Baird Medical Investment (NASDAQ:BDMD) Upgraded to “Hold” at Wall Street Zen

Baird Medical Investment (NASDAQ:BDMD) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Baird Medical Investment in a research report on Thursday, October 30th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Baird Medical Investment Stock Up 0.7%

Shares of Baird Medical Investment stock opened at $1.40 on Friday. The company has a fifty day moving average of $1.43 and a 200 day moving average of $2.59. Baird Medical Investment has a fifty-two week low of $1.02 and a fifty-two week high of $12.50.

Institutional Trading of Baird Medical Investment

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC purchased a new stake in Baird Medical Investment in the 3rd quarter worth $99,000. Jane Street Group LLC bought a new stake in shares of Baird Medical Investment in the second quarter worth about $142,000. Finally, Geode Capital Management LLC lifted its position in shares of Baird Medical Investment by 59.7% in the second quarter. Geode Capital Management LLC now owns 25,442 shares of the company’s stock worth $93,000 after buying an additional 9,511 shares in the last quarter. 19.78% of the stock is currently owned by institutional investors.

About Baird Medical Investment

Baird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.